B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $50.
Stocks · News reference
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earnings guidance. Other big gainers include CRNX, MAAS, and AGIO.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. futures rose, while Limoneira fell 8.4% after missing earnings and sales estimates. Resolution Minerals and Cooper led other premarket decliners.
JP Morgan Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $34
JP Morgan analyst Tessa Romero maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $31 to $34.
Citigroup Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $52
Citigroup analyst Samantha Semenkow maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $52.
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.